Biotechs, BIA, patient charities and investors: the power of relationships

NRG Therapeutics: Restoring motor neuron function via mitochondria

NRG raises $67M to test mitochondrial pore inhibitor in ALS

A UK biotech takes aim at Parkinson’s, ALS by drugging mitochondria

UK’s NRG Powers Up With £50m For Promising Mitochondrial Therapy

NRG raises $67 million for a small molecule for Parkinson’s and ALS

Stevenage, UK based NRG Therapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegenerative diseases like Parkinson's and ALS

A British mitochondrial startup wants to break ground in ALS and Parkinson's. It has £50M to try

Mitochondria: Movers and Shakers - a podcast about life with Parkinson's

Novel Parkinson’s therapy protects mitochondrial function

NRG Therapeutics launches Series B after $5m boost from Michael J. Fox Foundation

NRG Therapeutics gets grant to test mitochondria-targeting ALS therapy

Case Study: Life Sciences - Future50

9 neuroscience biotech companies you should know about

MJFF grant supports NRG Therapeutics' work to validate mitochondrial drug target for Parkinson's

Case Study: R&D grant funding

Parkinson’s disease drug hunters think outside the α-synuclein box

NRG raises Series A funds for Parkinson’s and ALS therapy development

Funding for NRG Therapeutics to work on mitochondria link to Parkinson’s and ALS

NRG announces £16m Series A for IND for Parkinson’s and ALS

Following the path to a new drug, together

NRG Therapeutics Scores $18M to Target Mitochondrial Dysfunction in Parkinson's, ALS

Omega Funds leads £16m Series A round for NRG Therapeutics

NRG closes £16M series A to fund fight against neurodegenerative diseases

GSK vets theorize that a mitochondrial target may unlock Parkinson's and ALS treatments in new startup